

Special Issue

State-of-the-Art Hepatitis Research in 2022

Message from the Guest Editor

In recent decades, numerous studies focused on the virology, epidemiology, immunology, genetics, molecular biology, natural history, pathogenesis, current drug treatment, and new drug development in hepatitis research have strengthened our knowledge in this field. Such research provides the chance to identify and develop vaccines and treatments or cure viral hepatitis infections. Therefore, we welcome contributions to this Special Issue of *Viruses*, “State-of-the-Art Hepatitis Research in 2022”. The aim is to provide comprehensive information on all aspects of hepatitis research. Contributions to this Special Issue will advance our knowledge of hepatitis induced by virus infections and provide a better understanding of this serious human pathogen. This Special Issue will bring together original research papers and review manuscripts on hepatitis research with a focus on acute/chronic viral replication, pathogenesis, immune responses, vaccine development, hepatic disease, and antiviral treatments in viral hepatitis research.

Guest Editor

Dr. Youkyung Choi

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, The Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/110888

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).